FCMI
OREX

Foresite Capital Management II’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Foresite Capital Management II’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-8,500
Closed -$179K – 29
2015
Q3 		$179K Sell
8,500
-3,500
-29% -$120K 0.05% 29
2015
Q2 		$594K Buy
+12,000
New +$717K 0.21% 21
2015
Q1 		– Sell
-25,150
Closed -$1.52M – 24
2014
Q4 		$1.52M Buy
+25,150
New +$1.26M 1.04% 20

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
GL
GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Foresite Capital Management II's OREX Position: Q4 2017 in Review

Foresite Capital Management II sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2017, closing a stake of 523,132 shares — an estimated $1.11M sold.

Foresite Capital Management II first reported a position in OREX in Q4 2014 and held it in 12 quarters. The position peaked at $32.9M in Q1 2015. 41 funds tracked by Wall St. Rank hold OREX as of Q4 2017.

  • Foresite Capital Management II reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Foresite Capital Management II sold 523,132 Orexigen Therapeutics, Inc. shares in Q4 2017, an estimated $1.11M.
  • Foresite Capital Management II first reported a position in Orexigen Therapeutics, Inc. in Q4 2014 and held it in 12 quarters.
  • Foresite Capital Management II's Orexigen Therapeutics, Inc. position peaked at $32.9M in Q1 2015.
  • 41 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2017.

Based on Foresite Capital Management II's 13F filing for Q4 2017, filed 13 Feb 2018.